NVO Novo Nordisk Stock Outlook 2026: GLP-1 Dominance Under Pressure
NVO Novo Nordisk stock outlook for 2026. Wegovy and Ozempic franchise vs Eli Lilly competition, CagriSema REDEFINE trial setback, IRA Medicare drug pricing risk, amycretin pipeline, and three-scenario valuation analysis for US investors.
NVO Novo Nordisk GLP-1